138
Participants
Start Date
December 17, 2020
Primary Completion Date
August 16, 2023
Study Completion Date
December 4, 2025
Trastuzumab deruxtecan
T-DXd: administered as an IV infusion
Durvalumab
Durvalumab: administered as an IV infusion
Paclitaxel
Paclitaxel: administered as an IV infusion
Capivasertib
Capivasertib: administered orally
Anastrozole
Anastrozole: administered orally
Fulvestrant
Fulvestrant: administered as an IM injection
Capecitabine
Capecitabine: administered orally
Research Site, Taipei
Research Site, Taipei
Research Site, Taipei
Research Site, Taoyuan District
Research Site, Ottignies
Research Site, Westmead
Research Site, Edegem
Research Site, Leuven
Research Site, East Melbourne
Research Site, New York
Research Site, New York
Research Site, Harrison
Research Site, Taipei
Research Site, Uniondale
Research Site, Commack
Research Site, Chapel Hill
Research Site, Chattanooga
Research Site, Germantown
Research Site, Taichung
Research Site, Monterrey
Research Site, Fort Worth
Research Site, Kaohsiung City
Research Site, Villejuif
Research Site, Moscow
Research Site, Moscow
Research Site, Saint Petersburg
Research Site, Goiânia
Research Site, Porto Alegre
Research Site, Porto Alegre
Research Site, São Paulo
Research Site, São Paulo
Research Site, Kelowna
Research Site, Québec
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Lead Sponsor
Collaborators (1)
Daiichi Sankyo Co., Ltd.
INDUSTRY
Daiichi Sankyo Company, Limited
UNKNOWN
AstraZeneca
INDUSTRY